Quick Answer
Zentalis Pharmaceuticals, Inc. reported Diluted EPS of $1.91 per share (loss) for fiscal year 2025.
Zentalis Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.91 | +18.0% |
| 2024 | -$2.33 | +47.9% |
| 2023 | -$4.47 | +0.2% |
| 2022 | -$4.48 | -20.4% |
| 2021 | -$3.72 | +11.2% |
| 2020 | -$4.19 | +48.7% |
| 2019 | -$8.16 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.37 | +33.9% | +0.0% |
| June 30, 2025 | -$0.37 | +70.2% | +44.8% |
| March 31, 2025 | -$0.67 | -578.6% | -19.6% |
| September 30, 2024 | -$0.56 | +29.1% | +54.8% |
| June 30, 2024 | -$1.24 | +33.0% | -985.7% |
| March 31, 2024 | $0.14 | +113.1% | +117.7% |
| September 30, 2023 | -$0.79 | +17.7% | +57.3% |
| June 30, 2023 | -$1.85 | -38.1% | -72.9% |
- Zentalis Pharmaceuticals, Inc. showed an increase of +18.0% in Diluted EPS compared to the prior fiscal year.
- Over the 2019–2025 period, Zentalis Pharmaceuticals, Inc.’s diluted eps has grown by 76.6% (from $8.16 per share (loss) to $1.91 per share (loss)).
- The most recent figure is from Zentalis Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: